Anton Dalsätt
Founding Editor & Reporter
Anton Dalsätt is a founding editor and reporter at media.age.house, covering healthtech, longevity startups, funding, and emerging science. He is also a co-founder of AGE.HOUSE, the Swedish nonprofit that owns and operates the publication.
Articles (6)
Avaí Bio and Austrianova Present an Encapsulated-Cell Approach to α-Klotho
At the Second Annual Klotho Conference, the companies described implanted cells, protected inside Austrianova’s Cell-in-a-Box capsules, that are meant to secrete α-Klotho over a long period.
L-Nutra Marks 10 Years of Prolon and Closes an $83.5 Million Series D
The Los Angeles company says two recent human trials found that its fasting-mimicking diet induced autophagy and lowered biological age by an average of 2.5 years after three cycles.
Insilico Launches Longevity Vaccines Research to Clear Early Drivers of Aging
The program uses generative AI and circular mRNA to design single-dose, self-limiting therapies that direct a patient’s own T cells against the cells that start age-related disease, beginning with the immune system.
BioViva Secures a U.S. Patent for an hTERT and Follistatin Gene-Therapy Approach
U.S. Patent No. 12,653,907 covers methods that combine hTERT and Follistatin-344 for age-related disorders, including approaches tied to telomere length, muscle mass, and blood glucose.
Human Longevity Offers 30x Whole-Genome Sequencing for USD 599
The company’s Genomics for All service sequences a person’s complete genome and uses an AI-powered app to report inherited risks, drug-response markers, and new interpretations as the science changes.
Czech Medtech HTG Medical Wins EU Certification and Passes €1M to Automate ICU Care
The HTG Urogram automates one of the ICU's most mundane hourly tasks — measuring a patient's urine output — and feeds it straight into hospital systems. Now CE-marked and past €1M in funding, the startup is heading for global markets.